IPCA Laboratories Ltd
NSE:IPCALAB

Watchlist Manager
IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd
NSE:IPCALAB
Watchlist
Price: 1 581.7 INR -0.26% Market Closed
Market Cap: 401.3B INR
Have any thoughts about
IPCA Laboratories Ltd?
Write Note

Gross Margin
IPCA Laboratories Ltd

67.4%
Current
64%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.4%
=
Gross Profit
57.5B
/
Revenue
85.3B

Gross Margin Across Competitors

Country IN
Market Cap 401.3B INR
Gross Margin
67%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 754.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

IPCA Laboratories Ltd
Glance View

Market Cap
401.3B INR
Industry
Pharmaceuticals

In the bustling corridors of the global pharmaceutical industry, IPCA Laboratories Ltd. stands as a formidable presence, deeply rooted in its commitment to innovative healthcare solutions. Established with a mission to enhance patient well-being, IPCA has grown from a modest formulation company in India into a multinational endeavor, celebrated for its prowess in the realms of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. This vertically integrated company meticulously controls every element of its production chain, securing its position as a trusted supplier to some of the world's leading pharmaceutical giants. IPCA's robust portfolio includes a wide array of therapeutic segments, from antimalarials and analgesics to antihypertensives and nutraceuticals, showcasing its versatility and comprehensive grasp over diverse medical needs. What sets IPCA apart in the crowded pharmaceutical landscape is its strategic blend of cutting-edge research, efficient manufacturing practices, and a global distribution network. The company invests significantly in research and development, channeling innovation into its drug development processes to sustain its competitive edge. Enhanced production capabilities at its state-of-the-art facilities ensure that IPCA not only meets stringent international standards but also operates at optimal cost efficiency. This enables the company to leverage economies of scale, thereby maximizing profitability. By exporting to over 100 countries and employing a robust marketing strategy, IPCA ensures its products have a wide reach across developed and emerging markets. Thus, through its integrated approach to drug development and distribution, IPCA Laboratories continues to cultivate a steady stream of revenue while contributing substantially to global healthcare.

IPCALAB Intrinsic Value
1 236.48 INR
Overvaluation 22%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.4%
=
Gross Profit
57.5B
/
Revenue
85.3B
What is the Gross Margin of IPCA Laboratories Ltd?

Based on IPCA Laboratories Ltd's most recent financial statements, the company has Gross Margin of 67.4%.